LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Search

Myomo Inc

Закрыт

0.63 -5.97

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.63

Макс.

0.67

Ключевые показатели

By Trading Economics

Доход

-151K

-3.8M

Продажи

1.3M

11M

Рентабельность продаж

-33.593

Сотрудники

194

EBITDA

763K

-2.3M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+517.14% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.5M

27M

Предыдущая цена открытия

6.6

Предыдущая цена закрытия

0.63

Myomo Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 мар. 2026 г., 23:15 UTC

Главные новостные события

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 мар. 2026 г., 22:36 UTC

Главные новостные события

Australian Government Rules Out Boots on the Ground in the Middle East

30 мар. 2026 г., 22:13 UTC

Приобретения, слияния, поглощения

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 мар. 2026 г., 21:00 UTC

Отчет

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 мар. 2026 г., 20:15 UTC

Главные новостные события

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 мар. 2026 г., 23:40 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

30 мар. 2026 г., 23:40 UTC

Обсуждения рынка

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 мар. 2026 г., 23:36 UTC

Обсуждения рынка

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 мар. 2026 г., 23:12 UTC

Обсуждения рынка

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 мар. 2026 г., 22:49 UTC

Обсуждения рынка

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 мар. 2026 г., 22:44 UTC

Обсуждения рынка

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 мар. 2026 г., 22:43 UTC

Обсуждения рынка

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 мар. 2026 г., 22:42 UTC

Обсуждения рынка

South32 Should Go for Growth, Says New Bull -- Market Talk

30 мар. 2026 г., 22:18 UTC

Обсуждения рынка

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 мар. 2026 г., 22:05 UTC

Обсуждения рынка

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 мар. 2026 г., 21:58 UTC

Приобретения, слияния, поглощения

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 мар. 2026 г., 21:39 UTC

Приобретения, слияния, поглощения

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 мар. 2026 г., 21:38 UTC

Приобретения, слияния, поглощения

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 мар. 2026 г., 21:36 UTC

Приобретения, слияния, поглощения

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 мар. 2026 г., 21:25 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

30 мар. 2026 г., 21:25 UTC

Обсуждения рынка

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 мар. 2026 г., 21:03 UTC

Приобретения, слияния, поглощения

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

30 мар. 2026 г., 20:09 UTC

Отчет

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 мар. 2026 г., 20:00 UTC

Главные новостные события

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Сравнение c конкурентами

Изменение цены

Myomo Inc Прогноз

Целевая цена

By TipRanks

517.14% рост

Прогноз на 12 месяцев

Средняя 4.32 USD  517.14%

Максимум 9.5 USD

Минимум 1.1 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Myomo Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
help-icon Live chat